Kathryn Nicole Weaver

Kathryn Nicole Weaver

Auto-generated profile, based on publicly available information

Kathryn Nicole Weaver

The Heart Institute, Division of Cardiology Cincinnati Children's Hospital, Cincinnati, Ohio, USA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA; Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
KWK. Nicole Weaver
K. Nicole Weaver
KWKristin E. Noack Watt
Kristin E. Noack Watt
RHRobert B Hufnagel
Robert B Hufnagel
JAJoaquin Navajas Acedo
Joaquin Navajas Acedo
LLLuke L. Linscott
Luke L. Linscott
HSHoward M. Saal
Howard M. Saal

1 August 2022 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
KWK. Nicole Weaver
K. Nicole Weaver
JCJing Chen
Jing Chen
ASAmy Shikany
Amy Shikany
PWPete S. White
Pete S. White
CPCarlos E. Prada
Carlos E. Prada
OIon behalf of the Pediatric Cardiac Genomics Consortium Investigators*
on behalf of the Pediatric Cardiac Genomics Consortium Investigators*
Background: Valvar pulmonary stenosis (vPS) accounts for 8% to 12% of congenital heart disease cases. Multiple genetic syndromes are associated with vPS, most commonly Noonan syndrome, but the cause is unknown in most cases. We analyzed genomic data from a large cohort with vPS to determine the prevalence of genetic diagnosis. Methods: The Pediatric Cardiac Genomics Consortium database was queried to identify probands with vPS without complex congenital heart disease or aneuploidy and with existing whole exome or genome sequencing. A custom analysis workflow was used to identify likely pathogenic or pathogenic variants in disease-associated genes. Demographic and phenotypic characteristics were compared between groups with and without molecular diagnoses. Results: Data from 119 probands (105 trios) were included. A molecular diagnosis was identified in 22 (18%); 17 (14%) had Noonan syndrome or a related disorder. Extracardiac and neurodevelopmental comorbidities were seen in 67/119 (56%) of probands. Molecular diagnosis was more common in those with extracardiac and neurodevelopmental phenotypes than those without (18/67 versus 4/52, P =0.0086). Conclusions: Clinicians should have high suspicion for a genetic diagnosis in individuals with vPS, particularly if additional phenotypes are present. Our results suggest that clinicians should consider offering sequencing of at least the known congenital heart disease and RASopathy genes to all individuals with vPS, regardless of whether that individual has extracardiac or neurodevelopmental phenotypes present.

18 April 2023 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
KSKelly Smallwood
Kelly Smallwood
KWKristin E.N. Watt
Kristin E.N. Watt
SISatoru Ide
Satoru Ide
KBKristina Baltrunaite
Kristina Baltrunaite
CBChad Brunswick
Chad Brunswick
KWK. Nicole Weaver
K. Nicole Weaver

14 October 2016 in Genes
Verified
Journal Article
Open access
PDF file
RGRose Gelineau-Morel
Rose Gelineau-Morel
MLMarshall Lukacs
Marshall Lukacs
KWK. Nicole Weaver
K. Nicole Weaver
RHRobert B Hufnagel
Robert B Hufnagel
DGDonald L. Gilbert
Donald L. Gilbert
RSRolf Stottmann
Rolf Stottmann
Whole exome sequencing continues to end the diagnostic odyssey for a number of patients and expands our knowledge of phenotypes associated with gene mutations. We describe an 11-year-old female patient with a constellation of symptoms including congenital cataracts, gut dysmotility, sensory neuropathy, and bifrontal polymicrogyria. Whole exome sequencing was performed and identified a de novo heterozygous missense mutation in the ATPase motor domain of cytoplasmic dynein heavy chain 1 (DYNC1H1), which is known to be involved in neuronal migration and retrograde axonal transport. The mutation was found to be highly damaging by multiple prediction programs. The residue is highly conserved, and reported mutations in this gene result in a variety of phenotypes similar to that of our patient. We report only the second case of congenital cataracts and the first of gut dysmotility in a patient with DYNC1H1, thus expanding the spectrum of disease seen in DYNC1H1 dyneinopathies.

8 August 2014 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
KWK. Nicole Weaver
K. Nicole Weaver
JJJodie Johnson
Jodie Johnson
BKBeth Kline-Fath
Beth Kline-Fath
XZXue Zhang
Xue Zhang
FLFoong-Yen Lim
Foong-Yen Lim
RHRobert J. Hopkin
Robert J. Hopkin

27 August 2020 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
KMK.W. Martin
K.W. Martin
NWN. Weaver
N. Weaver
Khalid AlhasanKhalid Alhasan
Khalid Alhasan
EGEVREN GUMUS
EVREN GUMUS
BSB.R. Sullivan
B.R. Sullivan
JSJulie Saba
Julie Saba
SUMMARY: SGPL1 encodes sphingosine-1-phosphate lyase, the final enzyme of sphingolipid metabolism. In 2017, a condition featuring steroid-resistant nephrotic syndrome and/or adrenal insufficiency associated with pathogenic SGPL1 variants was reported. In addition to the main features of the disease, patients often exhibit a range of neurologic deficits. In a handful of cases, brain imaging results were described. However, high-quality imaging results and a systematic analysis of brain MR imaging findings associated with the condition are lacking. In this study, MR images from 4 new patients and additional published case reports were reviewed by a pediatric neuroradiologist. Analysis reveals recurring patterns of features in affected patients, including isolated callosal dysgenesis and prominent involvement of the globus pallidus, thalamus, and dentate nucleus, with progressive atrophy and worsening of brain lesions. MR imaging findings of abnormal deep gray nuclei, microcephaly, or callosal dysgenesis in an infant or young child exhibiting other typical clinical features of sphingosine-1-phosphate lyase insufficiency syndrome should trigger prompt genetic testing for SGPL1 mutations.